Our work demonstrates the importance of the immune activation and coagulatory disorders in COVID-19 and strengthens the possible use of therapies to control both inflammatory disorders [43] and also platelet-based treatments such as the use of Bruton tyrosine kinase (Btk) to curb platelet activation, immunothrombosis, and the formation of platelet–neutrophil aggregates [44]. The gene discussed is BTK; the disease is COVID-19.